BSX Valuation

Boston Scientific Corp

Add to Watchlist

Advanced Chart

105.500

-0.25(-0.236%)1D

Overview
Forecast
Valuation
Earnings

BSX Relative Valuation

BSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BSX is overvalued; if below, it's undervalued.

Historical Valuation

Boston Scientific Corp (BSX) is now in the Overvalued zone, suggesting that its current forward PE ratio of 33.94 is considered Overvalued compared with the five-year average of 26.80. The fair price of Boston Scientific Corp (BSX) is between 77.30 to 98.74 according to relative valuation methord. Compared to the current price of 105.50 USD , Boston Scientific Corp is Overvalued By 6.84%.

Relative Value

Fair Zone

77.30-98.74

Current Price：105.50

6.84%

Overvalued

33.94

Trailing

Forward

27.31

EV/EBITDA

Boston Scientific Corp. (BSX) has a current EV/EBITDA of 27.31. The 5-year average EV/EBITDA is 21.17. The thresholds are as follows: Strongly Undervalued below 14.06, Undervalued between 14.06 and 17.61, Fairly Valued between 24.73 and 17.61, Overvalued between 24.73 and 28.29, and Strongly Overvalued above 28.29. The current Forward EV/EBITDA of 27.31 falls within the Overvalued range.

29.07

EV/EBIT

Boston Scientific Corp. (BSX) has a current EV/EBIT of 29.07. The 5-year average EV/EBIT is 23.14. The thresholds are as follows: Strongly Undervalued below 16.06, Undervalued between 16.06 and 19.60, Fairly Valued between 26.68 and 19.60, Overvalued between 26.68 and 30.22, and Strongly Overvalued above 30.22. The current Forward EV/EBIT of 29.07 falls within the Overvalued range.

7.49

Boston Scientific Corp. (BSX) has a current PS of 7.49. The 5-year average PS is 5.54. The thresholds are as follows: Strongly Undervalued below 3.28, Undervalued between 3.28 and 4.41, Fairly Valued between 6.67 and 4.41, Overvalued between 6.67 and 7.80, and Strongly Overvalued above 7.80. The current Forward PS of 7.49 falls within the Overvalued range.

32.01

P/OCF

Boston Scientific Corp. (BSX) has a current P/OCF of 32.01. The 5-year average P/OCF is 28.59. The thresholds are as follows: Strongly Undervalued below 16.69, Undervalued between 16.69 and 22.64, Fairly Valued between 34.54 and 22.64, Overvalued between 34.54 and 40.49, and Strongly Overvalued above 40.49. The current Forward P/OCF of 32.01 falls within the Historic Trend Line -Fairly Valued range.

51.43

P/FCF

Boston Scientific Corp. (BSX) has a current P/FCF of 51.43. The 5-year average P/FCF is 36.33. The thresholds are as follows: Strongly Undervalued below 19.65, Undervalued between 19.65 and 27.99, Fairly Valued between 44.67 and 27.99, Overvalued between 44.67 and 53.02, and Strongly Overvalued above 53.02. The current Forward P/FCF of 51.43 falls within the Overvalued range.

Boston Scientific Corp (BSX) has a current Price-to-Book (P/B) ratio of 6.97. Compared to its 3-year average P/B ratio of 5.11 , the current P/B ratio is approximately 36.25% higher. Relative to its 5-year average P/B ratio of 4.50, the current P/B ratio is about 54.80% higher. Boston Scientific Corp (BSX) has a Forward Free Cash Flow (FCF) yield of approximately 2.23%. Compared to its 3-year average FCF yield of 1.62%, the current FCF yield is approximately 37.52% lower. Relative to its 5-year average FCF yield of 1.85% , the current FCF yield is about 20.68% lower.

6.97

P/B

Median3y

5.11

Median5y

4.50

2.23

FCF Yield

Median3y

1.62

Median5y

1.85

Competitors Valuation Multiple

The average P/S ratio for BSX's competitors is 7.12, providing a benchmark for relative valuation. Boston Scientific Corp Corp (BSX) exhibits a P/S ratio of 7.49, which is 5.09% above the industry average. Given its robust revenue growth of 22.84%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BSX.N

Boston Scientific Corp

Intuitive Surgical Inc

Thermo Fisher Scientific Inc

Performance Decomposition

Market capitalization of BSX increased by 25.89% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 7.82 to 15.71.

The secondary factor is the Revenue Growth, contributed 22.84%to the performance.

Overall, the performance of BSX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

22.84%

4.12B → 5.06B

Revenue Growth

100.90%

7.82 → 15.71

Margin Expansion

-97.85%

2.92K → 62.79

P/E Change

25.89%